![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Bentham Science Publishers
E-ISSN: 1873-4286|21|18|2468-2486
ISSN: 1381-6128
Source: Current Pharmaceutical Design, Vol.21, Iss.18, 2015-06, pp. : 2468-2486
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Immunomodulatory treatment for myasthenia gravis
Inpharma, Vol. 1, Iss. 1283, 2001-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Myasthenia Gravis: Therapy Is Complex
Pharmaceutical Innovation, Vol. 11, Iss. 2, 2002-03 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Diagnosis and Management of Autoimmune Myasthenia Gravis
Clinical Drug Investigation, Vol. 31, Iss. 1, 2011-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Fluoroquinolones linked with myasthenia gravis exacerbation
Reactions Weekly, Vol. 1, Iss. 1370, 2011-01 ,pp. :